Established in June 2018, Hangzhou Apeloa Research Institute Co. Ltd. is the drug preparation research and development platform of Apeloa Pharmaceuticals Co. Ltd. Located in the Medicine Port Town of Qiantang District, Hangzhou City. FollowsApeloa's strategy of "making better FDF" and the development strategy of "multi-product" FDFs, It focuses on independent intellectual property product innovation, building a competitive R&D system. Utilizing the advantage of "integration of raw materials and FDF" of Apeloa, the company has built and established diversified FDF development platforms with high technological barriers, such as controlled release FDFs, non-homogeneous liquid FDFs, taste masking technology and digital preparation process.

The Institute focuses on building a differentiated product development pipeline based on clinical and market value; Equipped with internationally advanced FDFresearch and development equipments and instruments Product declaration area covers all major markets in the world, including China, the United States, Europe and WHO.

R & D equipment mainly include: high shear wet granulation machine、Alexanderwerk dry granulator, multifunctional fluidised bed, double-layer tablet press, high-efficiency coating machine, Telstar lyophiliser, air-flow pulveriser, etc;

R&D instruments include: High Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Inductively Coupled Plasma-Mass Spectrometer (ICP-MS), Ultra Performance Liquid Chromatograph (UPLC), Dissolution Meter, Mastersizer 3000 Laser Particle Sizer, Differential Scanning Calorimeter (DSC), Dynamic Moisture Sorption (DVS), TMS Texture Meter, INSENT Taste Analysis System, etc;

The dosage forms under development: immediate-release, enteric-coated, extended-release tablets, minitabs, bilayer tablets, dispersible tablets, dry suspension, granules, solution, small aqueous injections and lyophilised powder injections;

It covers therapeutic areas such as psychiatric, anti-infective, cardiovascular and cerebrovascular.